Skip to main
PGNY

Progyny (PGNY) Stock Forecast & Price Target

Progyny (PGNY) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 33%
Buy 56%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Progyny is a leading fertility benefits management company with a stable business and a high retention rate among its clients. The company's relationships with clients are managed closely, and it is actively working to expand and retain them. While the reduction in expected covered lives may cause investor concerns, the company's guidance appears conservative and reflects past patterns when excluding the impact of Amazon's transition of services. The company's valuation is compelling, but further proof points of the 2026 selling season may be needed to alleviate investor fears, making a HOLD rating appropriate for now.

Bears say

Progyny is facing potential headwinds from economic uncertainty and competition from traditional health plan carriers and private tech-enabled health companies. Additionally, changes in government regulations could negatively impact their ability to provide fertility and family-building benefits. While the company has potential for growth with their Progyny Select offering and expanding into new markets, it is still too early to determine the impact on their pipeline for the year. It remains to be seen if the company can achieve its goals and overcome potential challenges in a changing healthcare landscape.

Progyny (PGNY) has been analyzed by 9 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 56% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Progyny and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Progyny (PGNY) Forecast

Analysts have given Progyny (PGNY) a Buy based on their latest research and market trends.

According to 9 analysts, Progyny (PGNY) has a Buy consensus rating as of May 31, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Progyny (PGNY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.